PUBLICATION

Pharmaceutical Technology

AUTHORS

Ozgur Erguney, Sam Joll, Miyese Ozcan

DOWNLOAD THE FULL PDF

Belgium Pharmaceuticals 2009 Pharmaceutical Technology Release

Pharma & Life Sciences

Belgium

September 02, 2009

Belgium is one of the largest centers for pharmaceutical distribution and has the second highest number of pharmaceuticals exports per capita worldwide. In addition to attracting foreign companies, the country has also produced its own international heavyweights. But how will this small European country fare against its neighboring European giants and will it survive the threat of the emerging players as the global pharmaceutical industry faces turbulent times?

RELATED INTERVIEWS MORE INTERVIEWS

Bassil Dahiyat

PRESIDENT AND CEO, XENCOR

Powered by its XmAb antibody engineering platform, Xencor is developing a broad pipeline of drug candidates that are optimized to treat autoimmune disorders, cancer, asthma and allergic diseases.

United States

Pharma & Life Sciences

Peter DeYoung

CEO, PIRAMAL

Piramal Pharma updates GBR in its recent developments and prospects.

Pharma & Life Sciences

India

Barbara Weber

CEO, TANGO THERAPEUTICS

Tango Therapeutics is targeting unaddressed disease mechanisms in cancer to develop transformational new drugs for patients.

United States

Pharma & Life Sciences

David Cory

CEO, EIGER BIOPHARMACEUTICALS

Founded in 2008, Eiger BioPharmaceuticals is a late-stage biopharmaceutical company focused on developing and commercializing targeted therapies for rare diseases.

United States

Pharma & Life Sciences

Finding Funding: The Diversification of the Biotech Financing Landscape

United States Biopharmaceuticals 2018

The methods of financing biotech R&D are evolving as large pharma companies and governments look to small biotech start-ups to provide the next generation of medicines.

Pharma & Life Sciences

Turkey

A West-Meets-East Of The Pharma Industry

Turkey Pharmaceuticals & Biopharmaceuticals 2020

Portrait of the Turkey Pharmaceuticals industry.

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.

MORE PREVIOUSLY PUBLISHED